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Editorial
Albuminuria and Cognitive Performance: New Evidence for
Consideration of a Risk Factor Precursor Model From the
Maastricht Study
Related Article, p. 179
Albuminuria has been associated with lowercognitive functioning in some studies, but not
in others. Reviews1,2 and editorials3 have discussed
possible reasons for mixed results. Variable sample
sizes, limited test batteries, different study pop-
ulations and experimental designs, and variable
adjustment for cardiovascular risk factors and other
comorbid conditions may contribute to inconsistent
ﬁndings. The study by Martens et al4 in this issue of
AJKD supports a relationship between albuminuria
and cognitive functioning and addresses a number of
these methodological issues.
Martens et al4 used data from 2,987 participants,
age range 40 to 75 years, from the Maastricht Study,
a study focusing on the cause, pathophysiology,
complications, and comorbid conditions associated
with type 2 diabetes. In cross-sectional analyses, the
associations of estimated glomerular ﬁltration rate
(eGFR) and urinary albumin excretion (UAE) with
cognition were assessed. Two 24-hour urine collec-
tions were used to quantify UAE, while eGFR was
determined from serum creatinine and serum cystatin
C levels. The neurocognitive test battery assessed
memory function, information processing speed, and
executive function (Table 1). In analyses adjusted for
demographic characteristics, including education
level, lifestyle factors, depression, and cardiovascular
disease risk factors and treatments, individuals with
higher UAE, deﬁned as $30 mg/24 h, had poorer
information processing speed than those with
UAE , 15 mg/24 h. Associations of UAE with
memory function and executive function were sig-
niﬁcant in univariate and more parsimoniously
adjusted models, but were attenuated with multivar-
iable adjustment. No signiﬁcant associations were
found between eGFR and cognitive outcomes
following multivariable adjustment. Interaction terms
suggested that for both higher UAE and lower
eGFR, associations with cognitive outcomes were
somewhat higher among older than among younger
participants.
The interaction between albumin and age (contin-
uously distributed) was reported for 3 cognitive
measures in a secondary analysis. Speciﬁcally, for
each 10-year older age and each doubling of UAE,
there was a 3.1% decrease in the score for overall
cognitive performance (P 5 0.01), a 2.6% decrease in
information processing speed (P 5 0.05), and a 3.4%
decrease in executive function (P 5 0.02). Martens
et al raise the possibility that this phenomenon may
have been related to better cognitive or brain reserve
in the younger participants. Many other explanations
have been advanced, including interacting inﬂuences
of age versus disease process.5
It is important to note that the memory domain
operationally deﬁned by Martens et al is “working
memory.” Many other domains of memory can be
operationalized, including episodic memory (memory
for places and things) and semantic memory (memory
for general factual knowledge independent of per-
sonal experience). These and other memory domains
are important in the differential diagnoses of vascular
dementia, Alzheimer disease, and mixed-type
dementia.6 Studies comparing working, episodic,
and semantic memory outcomes are needed, and it is
desirable to operationally deﬁne and measure multiple
cognitive domains, taking patient burden into
consideration.7,8
As discussed, eGFR was not related to any measure
of cognition in adjusted analyses. In other investiga-
tions, signiﬁcant associations between eGFR and
cognition have been reported and often parallel those
for albuminuria.1-3 Of note, only 3.7% of partici-
pants (n5 111) in the Martens et al study had
eGFRs , 60 mL/min/1.73 m2, the cut point for
deﬁning chronic kidney disease (CKD) stage 3,
whereas 8% (n 5 239) exhibited high UAE values
($30 mg/24 h). The low prevalence of advanced CKD
in this sample could contribute to the lack of signiﬁcant
ﬁndings for executive functioning and working mem-
ory because many studies report relations between
kidney function and cognition only when evaluating a
population with a broader range of eGFRs, including
more individuals with CKD stages 3 to 5.1-3
This study has several strengths. In addition to its
well-deﬁned cohort, Martens et al used a carefully
selected set of statistical analyses with adjustment for a
substantial number of comorbid conditions, lifestyle,
and cardiovascular risk factors, introduced in hierar-
chical blocks; used 2 measures of UAE; and included
both creatinine and cystatin C levels in estimating
GFR. In the rest of this editorial, we summarize the
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contributions of this study to our understanding of
relations between kidney disease markers and cogni-
tive performance, discussing these relations in the
context of a risk-factor precursor model.
The attenuation in the magnitude of associations
between UAE and information processing speed with
adjustment for cardiovascular disease risk factors
could be explained by a risk factor precursor model.5,9
In this model, relations between albuminuria and
cognitive functioning may be due to the presence of
shared risk factors that precede clinically apparent
kidney disease.5,7 However, this explanation does not
exclude the possibility of the continued action of
these risk factors after exposure to albuminuria.
Cross-sectional studies, such as performed by Mar-
tens et al, make it difﬁcult to discover how much risk
factors and their associated comorbid conditions in-
ﬂuence cognition before versus after the development
of CKD.
In our own longitudinal research using eGFR as an
index of kidney function, we observed that cognitive
performance declined over 4.5 years following the
ﬁrst detection of reduced kidney function.7 Unfor-
tunately, we have found few studies in which either
the severity or duration of cardiovascular disease risk
factors, predating the development of kidney disease
deﬁned by either by albuminuria or eGFR, were
examined and adequately controlled for. Longitudi-
nal studies are necessary to assess whether cognitive
deﬁcits associated with albuminuria and eGFR are a
product of previous exposure to cardiovascular dis-
ease risk factors and events.
What does a difference in cognitive performance
at the level reported by Martens et al mean in terms
of treatment of and communication with a patient
presenting with albuminuria? Based on the effect
sizes observed, we would not argue that these pa-
tients should be singled out for special cognitive
interventions. Raw test scores in this study were
standardized, so the mean for each composite score
is zero, with a standard deviation (SD) of 1. This
allows us to present differences in cognitive func-
tioning across each of the domains indexed in the
same metric (the z score). The average difference in
information processing speed between participants
with elevated UAE ($30 mg/24 h) and the reference
group (UAE , 15 mg/24 h) was z 520.148
following adjustment for lifestyle and cardiovascular
disease risk factors. This translates to a 14.8%
decrease in information processing speed for those
with elevated UAE. These participants were per-
forming in the 44th percentile of a normal distribu-
tion. In clinical neuropsychology, dropping from a
previous level of performance by 1.0 SD (16th
percentile) is often considered clinically important.
In our previous study of eGFR, we deﬁned modest
and severe impairment in persons with early-stage
CKD as 1.0 and 1.5 SD (7th percentile) below the
mean, respectively.8 On average, participants with
albuminuria in the Martens et al study were not
Table 1. Operational Definitions of Test of Cognitive Ability in the Martens et al4 Study
Cognitive Domain Description of Cognitive Domain
Test Score Measures Used to Determine
Cognitive Domain (Composite) Scoresa
Memory function Abilities required to encode, store, and retrieve information
from memory; ie, working memory as opposed to passive
forms of memory
Verbal Learning Test: Immediate Recall
Verbal Learning Test: Delayed Recall
Information processing
speedb
Abilities involved in how much time it takes to detect and
mentally process information and execute a correct
response. Can be measured as time-expired, number of
correct responses in a specific period of time, or errors
Stroop Color-Word Test Part I
Stroop Color-Word Test Part II
Concept Shifting Test Part A
Concept Shifting Test Part B
Letter-Digit Substitution Test
Executive function Refers to a set of integrated mental processes necessary for
managing behavior to achieve an optimally successful or
appropriate response, including: attention, cognitive
flexibility, organizing, and problem solving and planning.
Places a heavy emphasis on ability to shift a response
when necessary
Stroop Color-Word Test Part III
Concept Shifting Test Part C
Overall cognitive
performance
Refers to a composite of the individual domains included in
the battery
A composite of the individual domains or
test scores
aSee Item S1 (available as online supplementary material) from Martens et al4 for more detail on measures used and calculations of
composite scores.
bInformation processing speed could also have been classified as speed/executive function because the measures used in the
Martens et al study require the use of executive function. For the information processing domain, the executive functioning test must be
done with the least mistakes made in a specific time.
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cognitively impaired in the clinical sense of the word
“impairment.” Of course, it must be acknowledged
that ﬁndings may have achieved clinical signiﬁcance
if more participants with advanced CKD had been
included in the sample.10
Of note, the level of performance reported for
participants in the Martens et al study is of epide-
miologic signiﬁcance in terms of their population-
level implications. If we could eliminate even
small changes in cognition associated with kidney
disease through prevention and treatment, func-
tioning would improve for many persons in the
population. Modest effect sizes observed for those
with albuminuria are good news in this regard
because they suggest that worse cognitive perfor-
mance associated with albuminuria is not insur-
mountable. There is a high likelihood that most
patients would respond to treatment and manage-
ment of cardiovascular and lifestyle variables or
prevention strategies. Hopefully the Marten et al
study will stimulate further research on the
hypothesis that lowered cognitive performance is
not caused by albuminuria, but that albuminuria
serves as a proxy for cardiovascular and cerebro-
vascular disease and therefore identiﬁes individuals
at risk for worse cognitive performance.
Merrill F. Elias, PhD, MPH
University of Maine
Orono, Maine
Rachael V. Torres, BA
Adam Davey, PhD
University of Delaware
Newark, Delaware
ACKNOWLEDGEMENTS
Support: None.
Financial Disclosure: The authors declare that they have no
relevant ﬁnancial interests.
Peer Review: Evaluated by a Co-Editor, Deputy Editor Weiner,
and Editor-in-Chief Levey.
REFERENCES
1. Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney
disease and cognitive impairment: a systematic review and meta-
analysis. Am J Nephrol. 2012;35(5):474-482.
2. Elias MF, Dore GA, Davey A. Kidney disease and cognitive
function. Contrib Nephrol. 2013;179:42-57.
3. Weiner DE. The cognition-kidney disease connection: les-
sons from population-based studies in the United States. Am J
Kidney Dis. 2008;52(2):201-204.
4. Martens RJH, Kooman JP, Stehouwer CDA, et al. Estimated
GFR, albuminuria, and cognitive performance: the Maastricht
Study. Am J Kidney Dis. 2017;69(2):179-191.
5. Waldstein S, Elias MF, eds. Neuropsychology of Cardiovas-
cular Disease. 2nd ed. New York, NY: Taylor and Francis; 2016.
6. Lopez OL, Wolk DA. Clinical evaluation: a systematic but
user-friendly approach. In: Wahlund LO, Erkinjuntti T,
Gauthier S, eds. Vascular Cognitive Impairment in Clinical
Practice. New York, NY: Cambridge Medicine; 2009:32-45.
7. Davey A, Elias MF, Robbins MA, Seliger SL, Dore GA.
Decline in renal functioning is associated with longitudinal decline
in global cognitive functioning, abstract reasoning, and verbal
memory. Nephrol Dial Transplant. 2013;28:1810-1819.
8. Torres RV, Elias MF, Seliger S, Davey A, Robbins MA.
Risk for cognitive impairment across 22 measures of cognitive
ability in early-stage chronic kidney disease [published online
ahead of print 2016]. Nephrol Dial Transplant. http://dx.doi.org/
10.1093/ndt/gfw005.
9. Fried L. Albuminuria and cognitive impairment. Clin J Am
Soc Nephrol. 2012;7. (3):376-378.
10. Murray AM. Cognitive impairment in the aging dialysis
and chronic kidney disease populations: an occult burden. Adv
Chronic Kidney Dis. 2008;15:123-132.
Am J Kidney Dis. 2017;69(2):163-165 165
Editorial
